Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Approves Heron Therapeutics Chemo Anti-Nausea Drug

By Stephanie Guzowski | August 11, 2016

Heron Therapeutics Inc.’s injectable therapy, Sustol (granisetron), for chemotherapy-induced nausea and vomiting (CINV) was approved by the U.S. Food and Drug Administration Wednesday.

Sustol is the first approved product that uses Heron’s Biochronomer drug-delivery technology, which maintained effective levels of the medication for at least five days, covering the acute and delayed phases of CINV. A global, Phase 3 program, composed of two, large clinical trials, evaluated Sustol’s efficacy and safety in more than 2,000 patients with cancer.

The newly approved drug is a serotonin-3 (5-HT3) receptor antagonist used in combination with other antiemetics.

Sustol had been rejected twice previously by the FDA. In 2010, Heron (then called A.P. Pharma) received its first rejection for Sustol. The company returned with additional data, but three years later, the drug was again rejected due to manufacturing and data analysis problems.

“Despite advances in the management of CINV, up to half of patients receiving chemotherapy can still experience CINV, with delayed CINV being particularly challenging to control,” said Dr. Ralph Boccia, medical director at the Center for Cancer and Blood Disorders, in the release. “In our experience, other 5-HT3 receptor antagonists, including palonosetron, are generally effective for 48 hours or less.”

CINV, one of the most acute side effects of chemotherapy, occurs in up to 80 percent of patients and has a significant impact on a patient’s quality of life, according to the National Cancer Institute.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50